File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome
  • Basic View
  • Metadata View
  • XML View
TitleSignificance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome
 
AuthorsSeto, WK1
Lai, CL1
Fung, J1
Wong, DKH1
Yuen, JCH1
Hung, IFN1
Yuen, MF1
 
Issue Date2011
 
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
 
CitationJournal of Hepatology, 2011, v. 55 n. 3, p. 522-528 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.jhep.2010.11.018
 
AbstractBACKGROUND and AIMS: The significance of early HBV DNA suppression during telbivudine treatment in predicting long-term outcomes needs further investigation. METHODS: We determined the cumulative rates of HBeAg seroconversion, ALT normalization, HBV DNA suppression (<12IU/ml) and telbivudine resistant mutations (using the highly sensitive line probe assay) for 117 treatment-native chronic hepatitis B (CHB) patients (61.5% HBeAg-positive) on telbivudine for 3years. The significance of serum HBV DNA at week 12 and 24 was compared. RESULTS: The median age and duration of follow-up were 39years and 24.2months, respectively. 117, 105, 69, and 43 patients had been followed up for at least 6months and 1, 2, and 3years, respectively. The cumulative rates of HBeAg seroconversion, ALT normalization, HBV DNA undetectability were 46.8%, 80.5%, and 51.2%, respectively, at 3years. There was an incremental increase in virologic breakthroughs to 39.5% by year 3. The cumulative rate of telbivudine resistant mutations was 4.8%, 17.6%, and 34.0% for year 1, 2, and 3, respectively. Week 12 HBV DNA of <200IU/ml was predictive of a higher chance of HBV DNA undetectability (p=0.022) and lower chance of resistance (p=0.001) by year 3. Undetectable HBV DNA at week 24 was predictive of viral suppression at year 2 (p<0.001) but not at year 3 (p=0.241). CONCLUSIONS: Continuous telbivudine resulted in improved biochemical and virologic outcomes, although there was an incremental increase in cumulative rate of resistance up to year 3. Week 12 HBV DNA of <200IU/ml was predictive of favorable long-term outcomes.
 
ISSN0168-8278
2012 Impact Factor: 9.858
2012 SCImago Journal Rankings: 2.797
 
DOIhttp://dx.doi.org/10.1016/j.jhep.2010.11.018
 
ISI Accession Number IDWOS:000293930600006
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorSeto, WK
 
dc.contributor.authorLai, CL
 
dc.contributor.authorFung, J
 
dc.contributor.authorWong, DKH
 
dc.contributor.authorYuen, JCH
 
dc.contributor.authorHung, IFN
 
dc.contributor.authorYuen, MF
 
dc.date.accessioned2011-08-26T14:24:12Z
 
dc.date.available2011-08-26T14:24:12Z
 
dc.date.issued2011
 
dc.description.abstractBACKGROUND and AIMS: The significance of early HBV DNA suppression during telbivudine treatment in predicting long-term outcomes needs further investigation. METHODS: We determined the cumulative rates of HBeAg seroconversion, ALT normalization, HBV DNA suppression (<12IU/ml) and telbivudine resistant mutations (using the highly sensitive line probe assay) for 117 treatment-native chronic hepatitis B (CHB) patients (61.5% HBeAg-positive) on telbivudine for 3years. The significance of serum HBV DNA at week 12 and 24 was compared. RESULTS: The median age and duration of follow-up were 39years and 24.2months, respectively. 117, 105, 69, and 43 patients had been followed up for at least 6months and 1, 2, and 3years, respectively. The cumulative rates of HBeAg seroconversion, ALT normalization, HBV DNA undetectability were 46.8%, 80.5%, and 51.2%, respectively, at 3years. There was an incremental increase in virologic breakthroughs to 39.5% by year 3. The cumulative rate of telbivudine resistant mutations was 4.8%, 17.6%, and 34.0% for year 1, 2, and 3, respectively. Week 12 HBV DNA of <200IU/ml was predictive of a higher chance of HBV DNA undetectability (p=0.022) and lower chance of resistance (p=0.001) by year 3. Undetectable HBV DNA at week 24 was predictive of viral suppression at year 2 (p<0.001) but not at year 3 (p=0.241). CONCLUSIONS: Continuous telbivudine resulted in improved biochemical and virologic outcomes, although there was an incremental increase in cumulative rate of resistance up to year 3. Week 12 HBV DNA of <200IU/ml was predictive of favorable long-term outcomes.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationJournal of Hepatology, 2011, v. 55 n. 3, p. 522-528 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.jhep.2010.11.018
 
dc.identifier.citeulike8451348
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.jhep.2010.11.018
 
dc.identifier.epage528
 
dc.identifier.hkuros189850
 
dc.identifier.hkuros211251
 
dc.identifier.isiWOS:000293930600006
 
dc.identifier.issn0168-8278
2012 Impact Factor: 9.858
2012 SCImago Journal Rankings: 2.797
 
dc.identifier.issue3
 
dc.identifier.openurl
 
dc.identifier.pmid21147187
 
dc.identifier.scopuseid_2-s2.0-84860390069
 
dc.identifier.spage522
 
dc.identifier.urihttp://hdl.handle.net/10722/137383
 
dc.identifier.volume55
 
dc.languageeng
 
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
 
dc.publisher.placeNetherlands
 
dc.relation.ispartofJournal of Hepatology
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAntiviral Agents - therapeutic use
 
dc.subject.meshHepatitis B virus - genetics
 
dc.subject.meshHepatitis B, Chronic - blood - drug therapy - virology
 
dc.subject.meshNucleosides - pharmacology - therapeutic use
 
dc.subject.meshPyrimidinones - pharmacology - therapeutic use
 
dc.titleSignificance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Seto, WK</contributor.author>
<contributor.author>Lai, CL</contributor.author>
<contributor.author>Fung, J</contributor.author>
<contributor.author>Wong, DKH</contributor.author>
<contributor.author>Yuen, JCH</contributor.author>
<contributor.author>Hung, IFN</contributor.author>
<contributor.author>Yuen, MF</contributor.author>
<date.accessioned>2011-08-26T14:24:12Z</date.accessioned>
<date.available>2011-08-26T14:24:12Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>Journal of Hepatology, 2011, v. 55 n. 3, p. 522-528</identifier.citation>
<identifier.issn>0168-8278</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/137383</identifier.uri>
<description.abstract>BACKGROUND and AIMS: The significance of early HBV DNA suppression during telbivudine treatment in predicting long-term outcomes needs further investigation. METHODS: We determined the cumulative rates of HBeAg seroconversion, ALT normalization, HBV DNA suppression (&lt;12IU/ml) and telbivudine resistant mutations (using the highly sensitive line probe assay) for 117 treatment-native chronic hepatitis B (CHB) patients (61.5% HBeAg-positive) on telbivudine for 3years. The significance of serum HBV DNA at week 12 and 24 was compared. RESULTS: The median age and duration of follow-up were 39years and 24.2months, respectively. 117, 105, 69, and 43 patients had been followed up for at least 6months and 1, 2, and 3years, respectively. The cumulative rates of HBeAg seroconversion, ALT normalization, HBV DNA undetectability were 46.8%, 80.5%, and 51.2%, respectively, at 3years. There was an incremental increase in virologic breakthroughs to 39.5% by year 3. The cumulative rate of telbivudine resistant mutations was 4.8%, 17.6%, and 34.0% for year 1, 2, and 3, respectively. Week 12 HBV DNA of &lt;200IU/ml was predictive of a higher chance of HBV DNA undetectability (p=0.022) and lower chance of resistance (p=0.001) by year 3. Undetectable HBV DNA at week 24 was predictive of viral suppression at year 2 (p&lt;0.001) but not at year 3 (p=0.241). CONCLUSIONS: Continuous telbivudine resulted in improved biochemical and virologic outcomes, although there was an incremental increase in cumulative rate of resistance up to year 3. Week 12 HBV DNA of &lt;200IU/ml was predictive of favorable long-term outcomes.</description.abstract>
<language>eng</language>
<publisher>Elsevier BV. The Journal&apos;s web site is located at http://www.elsevier.com/locate/jhep</publisher>
<relation.ispartof>Journal of Hepatology</relation.ispartof>
<subject.mesh>Antiviral Agents - therapeutic use</subject.mesh>
<subject.mesh>Hepatitis B virus - genetics</subject.mesh>
<subject.mesh>Hepatitis B, Chronic - blood - drug therapy - virology</subject.mesh>
<subject.mesh>Nucleosides - pharmacology - therapeutic use</subject.mesh>
<subject.mesh>Pyrimidinones - pharmacology - therapeutic use</subject.mesh>
<title>Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0168-8278&amp;volume=55&amp;issue=3&amp;spage=522&amp;epage=528&amp;date=2010&amp;atitle=Significance+of+HBV+DNA+levels+at+12+weeks+of+telbivudine+treatment+and+the+3+years+treatment+outcome</identifier.openurl>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/j.jhep.2010.11.018</identifier.doi>
<identifier.pmid>21147187</identifier.pmid>
<identifier.scopus>eid_2-s2.0-84860390069</identifier.scopus>
<identifier.hkuros>189850</identifier.hkuros>
<identifier.hkuros>211251</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-84860390069&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>55</identifier.volume>
<identifier.issue>3</identifier.issue>
<identifier.spage>522</identifier.spage>
<identifier.epage>528</identifier.epage>
<identifier.isi>WOS:000293930600006</identifier.isi>
<publisher.place>Netherlands</publisher.place>
<identifier.citeulike>8451348</identifier.citeulike>
</item>
Author Affiliations
  1. The University of Hong Kong